For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Pruritus is a sensation that causes the desire or reflex to scratch. Pruritus has resisted many attempts to classify it as any one type of sensory experience. Modern science has shown that Pruritus has many similarities to pain, and while both are unpleasant sensory experiences, their behavioral response patterns are different. Pain creates a withdrawal reflex, whereas Pruritus leads to a scratch reflex.
Scope of the Report:
This report studies the Pruritus Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Pruritus Therapeutics market by product type and applications/end industries.
Skin disease is the fourth leading cause of nonfatal disease burden. Skin diseases include eczema, psoriasis, acne vulgaris, pruritus, alopecia areata, decubitus ulcer, urticaria, scabies, fungal skin diseases, impetigo, abscess, and other bacterial skin diseases, cellulitis, viral warts, molluscum contagiosum, and non-melanoma skin cancer. Among these types, fungal skin diseases and pruritus were in the top 10 most prevalent diseases worldwide in 2010. Thus pruritus therapeutics market is growing with rising prevalence of skin diseases. Moreover, patent expiration of dermatitis drugs and the introduction of new products are also responsible for the growth of pruritus therapeutics market.
The classification of Pruritus Therapeutics includes Corticosteroids, Antihistamines, Calcineurin Inhibitors and other. The proportion of Antihistamines in 2016 is about 21.6%, and the proportion of Corticosteroids is about 22.9%.
North America is the largest consumption place, with a revenue market share nearly 43.4% in 2016. Following North America, Europe is the second largest consumption place with the revenue market share of 27.3%.
The global Pruritus Therapeutics market is valued at 11300 million USD in 2017 and is expected to reach 15000 million USD by the end of 2023, growing at a CAGR of 4.9% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Pruritus Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
- LEO Pharma
- UCB Pharma
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Calcineurin Inhibitors
Market Segment by Applications, can be divided into
- External Use